Medivir AB (publ) (LON:0GP7)

Market Cap	3.92M
Revenue (ttm)	314.54K
Net Income (ttm)	-6.14M
Shares Out	n/a
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,650
Average Volume	11,502
Open	0.5580
Previous Close	0.5700
Day's Range	0.5500 - 0.5580
52-Week Range	0.5010 - 3.0300
Beta	0.33
RSI	22.14
Earnings Date	Nov 6, 2025

About Medivir AB

Medivir AB (publ), a pharmaceutical company, focuses on the development and commercialization of treatments for cancer in Nordic region, rest of Europe, and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It is also developing Remetinostat HDAC inhibitor for treating MF cutaneous T-cell lymphoma and basal cell carcinoma, as well as squamous cell carcinoma. In addition, the company is developing MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1987
• Employees: 10
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GP7

Financial Performance

In 2024, Medivir AB's revenue was 3.48 million, a decrease of -54.36% compared to the previous year's 7.63 million. Losses were -123.32 million, 38.1% more than in 2023.

Financial numbers in SEK